Merus Labs International Inc. (NASDAQ:MSLI) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Merus Labs International Inc. is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The Company’s products include anti-infectives and wound care products. Merus Labs International Inc., formerly known as Envoy Capital Group Inc., is based in Vancouver, Canada. “

Several other research firms also recently issued reports on MSLI. Canaccord Genuity reaffirmed a “buy” rating on shares of Merus Labs International in a research note on Friday, August 12th. Paradigm Capital reissued a “hold” rating and issued a $1.60 target price (down previously from $1.75) on shares of Merus Labs International in a research note on Wednesday, October 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $4.41.

Analyst Recommendations for Merus Labs International (NASDAQ:MSLI)

Shares of Merus Labs International (NASDAQ:MSLI) opened at 0.965 on Wednesday. The firm’s market cap is $112.90 million. Merus Labs International has a 12 month low of $0.92 and a 12 month high of $1.90. The stock’s 50 day moving average is $1.00 and its 200 day moving average is $1.24.

Merus Labs International (NASDAQ:MSLI) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.03. Merus Labs International had a negative return on equity of 3.41% and a negative net margin of 12.89%. On average, analysts anticipate that Merus Labs International will post ($0.07) earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of MSLI. 1832 Asset Management L.P. boosted its stake in Merus Labs International by 6.9% in the first quarter. 1832 Asset Management L.P. now owns 9,767,818 shares of the company’s stock valued at $23,969,000 after buying an additional 627,200 shares during the period. Acadian Asset Management LLC boosted its stake in Merus Labs International by 48.3% in the second quarter. Acadian Asset Management LLC now owns 4,686,382 shares of the company’s stock valued at $5,956,000 after buying an additional 1,526,200 shares during the period. I.G. Investment Management LTD. boosted its stake in Merus Labs International by 58.9% in the second quarter. I.G. Investment Management LTD. now owns 1,655,500 shares of the company’s stock valued at $2,115,000 after buying an additional 613,500 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its stake in Merus Labs International by 68.4% in the second quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 1,352,981 shares of the company’s stock valued at $2,232,000 after buying an additional 549,530 shares during the period. Finally, Guardian Capital LP boosted its stake in Merus Labs International by 21.1% in the second quarter. Guardian Capital LP now owns 1,208,400 shares of the company’s stock valued at $1,533,000 after buying an additional 210,500 shares during the period. Institutional investors own 25.73% of the company’s stock.

About Merus Labs International

Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.

5 Day Chart for NASDAQ:MSLI

Receive News & Stock Ratings for Merus Labs International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc. and related stocks with our FREE daily email newsletter.